Published in Lancet Oncol on June 17, 2009
Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol (2011) 5.59
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst (2011) 4.59
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ (2014) 2.27
Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med (2012) 1.65
EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer (2012) 1.63
Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG (2012) 1.57
HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer (2012) 1.53
The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet (2012) 1.33
Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol (2011) 1.25
Trials comparing cytology with human papillomavirus screening. Lancet Oncol (2009) 1.09
Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol (2009) 1.03
Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition. J Gynecol Oncol (2013) 1.02
Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years. J Gen Intern Med (2016) 1.01
Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years. Br J Cancer (2014) 1.00
Further analysis of the ARTISTIC trial. Lancet Oncol (2009) 0.96
The dynamics of DNA methylation covariation patterns in carcinogenesis. PLoS Comput Biol (2014) 0.96
Performance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison with HC2 and PCR-based Linear Array. Infect Agent Cancer (2011) 0.95
MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women. J Natl Cancer Inst (2014) 0.92
New insights into cervical cancer screening. J Gynecol Oncol (2012) 0.92
Major clinical research advances in gynecologic cancer in 2013. J Gynecol Oncol (2014) 0.90
HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol (2015) 0.90
Major clinical research advances in gynecologic cancer in 2014. J Gynecol Oncol (2015) 0.90
Screening: HPV testing for cervical cancer: the good, the bad, and the ugly. Nat Rev Clin Oncol (2010) 0.89
Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females. ISRN Obstet Gynecol (2011) 0.89
Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study. J Clin Microbiol (2013) 0.89
Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. Br J Cancer (2010) 0.88
Is 58% sensitivity for detection of cervical intraepithelial neoplasia 3 and invasive cervical cancer optimal for cervical screening? Cytojournal (2014) 0.88
Sensitive HPV genotyping based on the flow-through hybridization and gene chip. J Biomed Biotechnol (2012) 0.87
The Korean guideline for cervical cancer screening. J Gynecol Oncol (2015) 0.87
Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice. Gynecol Oncol (2011) 0.86
A systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screening. Am J Obstet Gynecol (2012) 0.86
Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control. J Clin Microbiol (2014) 0.85
Major clinical research advances in gynecologic cancer in 2010. J Gynecol Oncol (2010) 0.85
Preferences for surveillance strategies for women treated for high-grade precancerous cervical lesions. Gynecol Oncol (2010) 0.83
[Computer-assisted diagnostics in cervical cytology]. Pathologe (2011) 0.83
Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J Natl Cancer Inst (2015) 0.83
Evaluation of the detection of 14 high-risk human papillomaviruses with HPV 16 and HPV 18 genotyping for cervical cancer screening. Exp Ther Med (2013) 0.83
Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology. PLoS One (2015) 0.82
Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. BMC Cancer (2015) 0.82
New strategies for human papillomavirus-based cervical screening. Womens Health (Lond Engl) (2013) 0.80
High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. J Clin Microbiol (2012) 0.80
Evaluation of the Oncogenic Human Papillomavirus DNA Test with Liquid-Based Cytology in Primary Cervical Cancer Screening and the Importance of the ASC/SIL Ratio: A Belgian Study. ISRN Obstet Gynecol (2014) 0.80
Human papillomavirus (HPV) E6/E7 mRNA detection in cervical exfoliated cells: a potential triage for HPV-positive women. J Zhejiang Univ Sci B (2017) 0.79
Prognostic value of HPV E6/E7 mRNA assay in women with negative colposcopy or CIN1 histology result: a follow-up study. PLoS One (2013) 0.79
Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening. Br J Cancer (2010) 0.79
HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice. Ecancermedicalscience (2012) 0.79
Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy. Int J Cancer (2011) 0.78
Is the UK ready to embrace HPV testing? Lancet Oncol (2009) 0.78
Tumour suppressor gene methylation and cervical cell folate concentration are determinants of high-risk human papillomavirus persistence: a nested case control study. BMC Cancer (2014) 0.78
Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer (2016) 0.78
Gynecological cancer: More evidence supporting human papillomavirus testing. Nat Rev Clin Oncol (2012) 0.78
Detection of high-risk human papillomavirus subtypes in cervical glandular neoplasia by in situ hybridization. Int J Clin Exp Pathol (2013) 0.78
Longitudinal analysis of carcinogenic human papillomavirus infection and associated cytologic abnormalities in the Guanacaste natural history study: looking ahead to cotesting. J Infect Dis (2011) 0.77
Past and future of prophylactic ablation of the cervical squamocolumnar junction. Ecancermedicalscience (2015) 0.76
A Single-Arm, Proof-Of-Concept Trial of Lopimune (Lopinavir/Ritonavir) as a Treatment for HPV-Related Pre-Invasive Cervical Disease. PLoS One (2016) 0.76
The route of science: Labyrinths and algorithms - Inspirations by human papillomavirus testing and cervical cancer. Cytojournal (2015) 0.75
The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia. J Clin Microbiol (2015) 0.75
3q26 amplification is an effective negative triage test for LSIL: a historical prospective study. PLoS One (2012) 0.75
The role of human papillomavirus testing after treatment for high-grade cervical dysplasia. J Gynecol Oncol (2015) 0.75
Cytology and human papillomavirus co-test results preceding incident high-grade cervical intraepithelial neoplasia. PLoS One (2015) 0.75
Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial. Br J Cancer (2016) 0.75
Previous cervical cytology and high-risk human papillomavirus testing in a cohort of patients with invasive cervical carcinoma in Shandong Province, China. PLoS One (2017) 0.75
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet (2007) 11.62
Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med (2009) 10.60
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
The cervical cancer epidemic that screening has prevented in the UK. Lancet (2004) 7.72
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26
A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet (2007) 6.02
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol (2011) 4.66
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Data protection, informed consent, and research. BMJ (2004) 4.25
Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nat Genet (2007) 3.93
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum (2006) 3.45
Clinical and economic impact of stress echocardiography compared with exercise electrocardiography in patients with suspected acute coronary syndrome but negative troponin: a prospective randomized controlled study. Eur Heart J (2007) 3.39
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine (2012) 3.09
Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst (2011) 3.05
Only the best: medical student selection in Australia. Med J Aust (2012) 3.00
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88
Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet (2003) 2.71
Comprehensive analysis of the contribution of germline MYH variation to early-onset colorectal cancer. Int J Cancer (2004) 2.53
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst (2004) 2.32
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis. Br J Psychiatry (2006) 2.09
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
The search for low-penetrance cancer susceptibility alleles. Oncogene (2004) 1.88
The Mesothelioma and Radical surgery randomized controlled trial: the Mars feasibility study. J Thorac Oncol (2009) 1.87
Search for low penetrance alleles for colorectal cancer through a scan of 1467 non-synonymous SNPs in 2575 cases and 2707 controls with validation by kin-cohort analysis of 14 704 first-degree relatives. Hum Mol Genet (2006) 1.84
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet (2007) 1.74
Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int (2004) 1.68
Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med (2012) 1.65
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
What are the most effective techniques in changing obese individuals' physical activity self-efficacy and behaviour: a systematic review and meta-analysis. Int J Behav Nutr Phys Act (2013) 1.64
Incidence of prostate cancer after termination of screening in a population-based randomised screening trial. Eur Urol (2013) 1.64
Cancer survival is dependent on season of diagnosis and sunlight exposure. Int J Cancer (2006) 1.64
Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case control study. Hum Mol Genet (2007) 1.61
Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet (2009) 1.58
Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. Nat Genet (2013) 1.58
A multicentre study on the reliability of qualitative and quantitative nail-fold videocapillaroscopy assessment. Rheumatology (Oxford) (2011) 1.57
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 1.56
Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet (2013) 1.56
Maternal high-fat-diet programs rat offspring liver fatty acid metabolism. Lipids (2015) 1.48
Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 1.47
The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen (2012) 1.46
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. Thromb Haemost (2009) 1.46
A randomized trial of exercise treadmill ECG versus stress SPECT myocardial perfusion imaging as an initial diagnostic strategy in stable patients with chest pain and suspected CAD: cost analysis. J Nucl Cardiol (2007) 1.46
The reliability of the clinical tests and questions recommended in international guidelines for low back pain. Spine (Phila Pa 1976) (2007) 1.45
The perinatal development of arterial pressure in sheep: effects of low birth weight due to twinning. Reprod Sci (2008) 1.44
Maternal LPS induces cytokines in the amniotic fluid and corticotropin releasing hormone in the fetal rat brain. Am J Physiol Regul Integr Comp Physiol (2004) 1.42
Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet (2003) 1.42
Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer. Hum Mol Genet (2008) 1.40
Eurogin 2010 roadmap on cervical cancer prevention. Int J Cancer (2011) 1.40
Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis (2008) 1.40
Cervical cancer screening programs in Latin America and the Caribbean. Vaccine (2008) 1.40
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet (2013) 1.39
Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis. J Natl Cancer Inst (2008) 1.36
Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer Res (2009) 1.35
A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer (2011) 1.34
The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet (2012) 1.33
Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Hum Mol Genet (2009) 1.33
From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett (2007) 1.33
High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG (2002) 1.33
N-acetyl-cysteine suppresses amniotic fluid and placenta inflammatory cytokine responses to lipopolysaccharide in rats. Am J Obstet Gynecol (2006) 1.32
Why are patients in clinical trials of heart failure not like those we see in everyday practice? J Clin Epidemiol (2003) 1.31
Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res (2007) 1.29
Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev (2009) 1.29
Systems analysis of eleven rodent disease models reveals an inflammatome signature and key drivers. Mol Syst Biol (2012) 1.27
11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat (2012) 1.26
ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet (2008) 1.25
Do interventions to promote walking in groups increase physical activity? A meta-analysis. Int J Behav Nutr Phys Act (2013) 1.25
Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.23
Maternal undernutrition influences placental-fetal development. Biol Reprod (2010) 1.22
Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet (2005) 1.20
The future of association studies of common cancers. Hum Genet (2003) 1.18
Uteroplacental insufficiency increases visceral adiposity and visceral adipose PPARgamma2 expression in male rat offspring prior to the onset of obesity. Early Hum Dev (2010) 1.17
Fetal programming of adult disease: implications for prenatal care. Obstet Gynecol (2011) 1.16